Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
Investigational New Drug Application reviewed and accepted Enrollment of US patients expected to begin in Q3 2019 Clinical trial authorizations now obtained in all twelve participating countries LYON, France and CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP -
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new manufacturing site in Princeton and extension of Lyon facility completed Cash position of €110.5
View HTML
Toggle Summary ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
LYON, France , May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , is announcing that the Board of Directors will
View HTML
Toggle Summary ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update
LYON, France , May 02, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2019 first
View HTML
More >>

Upcoming Events

There are currently no events to display.

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top